Evidence map›Paper›PMID 31783881›Full record

ArticleCritical care (London, England)2019

The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort.

Eleni Karakike, Evdoxia Kyriazopoulou, Iraklis Tsangaris, Christina Routsi, Jean-Louis Vincent, Evangelos J Giamarellos-Bourboulis

4 registry-linked trialsAbstract read
In one paragraph

Article in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00297674 phase4completednot on this map

Clarithromycin as Immunomodulatory Therapy for the Management of Septic Syndrome by Ventilator-Associated Pneumonia

TypeinterventionalSponsorUniversity of AthensRan2004 to 2005Enrolled200ConditionsSepsis, Ventilator Associated PneumoniaArmsIntravenous Clarithromycin
NCT01223690 phase3completednot on this map

A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis

TypeinterventionalSponsorUniversity of AthensRan2007 to 2011Enrolled600ConditionsSepsis, Severe Sepsis, Septic ShockArmsClarithromycin, Dextrose 5%
NCT04718623 unknown statusnot on this mapstarted 2021, after this paper: background citation

Evaluation of Presepsin and Syndecan-1 as Biomarkers for Early Diagnosis and Prognosis of Sepsis Following Major Surgeries

TypeobservationalSponsorAlexandria UniversityRan2021 to 2022Enrolled30ConditionsSepsis Following A Procedure, Diagnoses, Syndromes, and ConditionsArmsQuantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations
NCT06473844 narecruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial

TypeinterventionalSponsorHospital Authority, Hong KongRan2025 to 2027Enrolled60ConditionsSepsis, Inflammation, SGLT2 Inhibitors, Critically IllArmsEmpagliflozin 10 MG, Placebo
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eleni Karakike4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 1 Rimini Street, 12462, Athens, Greece.
Evdoxia Kyriazopoulou4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 1 Rimini Street, 12462, Athens, Greece.
Iraklis Tsangaris2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, 12462, Athens, Greece.
Christina Routsi1st Department of Critical Care Medicine, National and Kapodistrian University of Athens, 10676, Athens, Greece.
Jean-Louis VincentDepartment of Intensive Care, Erasme Hospital, Université libre de Bruxelles, 1070, Brussels, Belgium.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 1 Rimini Street, 12462, Athens, Greece. egiamarel@med.uoa.gr.ORCID 0000-0003-4713-3911

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the Sepsis-3 criteria, change in Sequential Organ Failure Assessment (SOFA) score has become a key component of sepsis identification. Thus, it could be argued that reversal of this change (Δ

methodsData from two previously published randomized controlled trials were studied: the first reporting on patients with severe Gram-negative infections as a derivation cohort and the second reporting on patients with ventilator-associated pneumonia as a validation cohort. Only patients with sepsis according to the Sepsis-3 definition were included in this analysis. SOFA scores were calculated on days 1, 2, 3, 5, 7, 14, and 28.

resultsWe included 448 patients within the derivation cohort and 199 within the validation cohort. Mean SOFA scores on day 1 were 6.06 ± 4.07 and 7.84 ± 3.39, and 28 day mortality 22.8% and 29.6%, respectively. In the derivation cohort, the earliest time point where Δ

conclusionsΔ

trial registrationClinicalTrials.gov numbers NCT01223690 and NCT00297674.

Indexed as

Organ Dysfunction ScoresPrognosisAgedArea Under CurveCohort StudiesFemaleHospital MortalityHumansMaleMiddle AgedOdds RatioRetrospective StudiesROC CurveSepsisStatistics, NonparametricDelta changeMortalitySepsisSequential Organ Failure Assessment (SOFA)Trial endpoints

Identifiers

PMID31783881
PMCPMC6884794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.